SRPT : Analysis & Opinions

  1. Sarepta Therapeutics' 3 Biggest Risks

    March 23, 2015
    There are arguably few diagnoses as frightening for children and their parents as Duchenne muscular dystrophy, or DMD. Based ...
  2. Should We Be Concerned For Sarepta’s Share Prices?

    March 2, 2015
    The disease that's caught the attention of a few biotech companies, including Sarepta Therapeutics , is Duchenne muscular ...
  3. A Look Back At The Year In Biotech

    December 28, 2012
    Biotech stocks have been major outpeformers in 2012.
  4. Alexion Pharmaceuticals and More Big Movers in Healthcare on ...

    December 7, 2012
    So far today, the Nasdaq is down 0.7%, the S&P 500 is unchanged and the Dow is trading up 0.3%. The healthcare sector ...
Trading Center